Laniquidar
From Wikipedia, the free encyclopedia
 |
|
|
Laniquidar
|
|
| Systematic (IUPAC) name | |
| 11-[1-[2-[4-(Quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,3-b][3]benzazepine-3-carboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C37H36N4O3 |
| Mol. mass | 584.70 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).[1]
[edit] References
- ^ Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;12;17(4):641-51. PMID 15494300
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
